Replies to post #267482 on Avid Bioservices Inc (CDMO)

[tradero]

Isn't it te other way around? Shift MERCK - AZN

Planned studies include bavituximab in combination with pembrolizumab (AZN ?, it should be MERCK) in hepatocellular carcinoma,and durvalumab (MERCK?) in NSCLC

[Protector]

itsabouttime, incorrect companies!

Planned studies include bavituximab in combination with pembrolizumab (AZN) in hepatocellular carcinoma,and durvalumab (MERCK) in NSCLC. Good

pembrolizumab is from MERCK and durvalumab from AZN. You switched them.